UBS: National Medical Insurance Drug List Negotiation Success Rate Stays High, Class 1 Innovative Drugs Hit Record

Stock News11-16 16:04

UBS has released a research report stating that the National Healthcare Security Administration has announced the 2026 National Medical Insurance Drug List and the Commercial Insurance Innovative Drug List. Of the 124 drugs that passed review as negotiation or bidding candidates, 107 were included in the medical insurance list, while another 34 were removed due to factors such as clinical substitution and supply, bringing the total number of drugs covered by the medical insurance list to 3,331, a year-on-year increase of 2.4%. The success rate of negotiations for the National Medical Insurance Drug List remains at a high level.

The bank noted that among the 107 newly included drugs, 51 are Class 1 innovative drugs, accounting for nearly half of the total new additions and setting a record high. All 12 negotiated drugs in the Commercial Insurance Innovative Drug List were also included. The bank believes this year's adjustment was broadly stable, with strong industry participation and a high negotiation success rate, though the extent of price reductions will only be confirmed after the two lists officially take effect on January 1, 2027.

On the pharmaceutical company side, Hansoh Pharma (03692), CSPC Pharma (01093), SBP Group (01177), Simcere Pharma (02096), and 3SBio (01530) all had products included or new indications added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment